Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29261403 | 0.87 | ALDH1A1 (0.31) | — | |
| SCHEMBL20165 | 0.83 | DHFR (0.33) | PNP | |
| SCHEMBL2512344 | 0.82 | SUMO1 (0.36) | PNP | |
| SCHEMBL26506 | 0.82 | SUMO1 (0.36) | PNP | |
| SCHEMBL7597747 | 0.81 | MPO (0.38) | MPO | |
| SCHEMBL29512549 | 0.80 | SUMO1 (0.36) | PNP | |
| SCHEMBL7607407 | 0.80 | MPO (0.40) | MPO | |
| SCHEMBL18132313 | 0.79 | — | — | |
| SCHEMBL20744797 | 0.79 | — | — | |
| SCHEMBL542389 | 0.79 | PNP (0.37) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | VICO THERAPEUTICS B.V. (NL) | 2026-05-28 | — | — | US | disclosed |
| WO-2026099473-A1 | OLIGONUCLEOTIDES WITH NEW INTERNUCLEOSIDE LINKAGE | VICO THERAPEUTICS B.V. (NL) | 2026-05-15 | — | — | WO | disclosed |
| EP-4728071-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-04-22 | — | — | EP | disclosed |
| EP-4713459-A2 | ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCS OR ANCS), COMPOSITIONS CONTAINING, AND THERAPEUTIC USE THEREOF | LIFORDI IMMUNOTHERAPEUTICS, INC. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4702143-A2 | COMPOSITIONS AND METHODS FOR TREATING STXBP1 DISORDERS | BioMarin Pharmaceutical Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-4702144-A1 | ANTISENSE OLIGOMERS FOR TREATMENT OF CHRONIC KIDNEY DISEASE | Sarepta Therapeutics, Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20260048076-A1 | METHODS FOR DECREASING OR INHIBITING HUMAN L1 RETROTRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN | ALTOS LABS, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4015631-B1 | NOVEL PROCESSES FOR THE PRODUCTION OF OLIGONUCLEOTIDES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-02-18 | — | — | EP | disclosed |
| EP-4688143-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF LIVER DISEASE | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| EP-4689110-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ProQR Therapeutics II B.V. (NL) | 2026-02-11 | — | — | EP | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| WO-2012144906-A1 | NEW COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE 1 (DM1) | PROSENSA TECHNOLOGIES B.V. (NL) | 2012-10-26 | — | — | WO | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2307565-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009152353-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-4879377-A | Nucleoside process | BRISTOL-MYERS COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0145978-B1 | NUCLEOSIDE PROCESS | Bristol-Myers Company (US) | 1989-04-19 | — | — | EP | disclosed |
| US-4625020-A | Nucleoside process | BRISTOL-MYERS COMPANY (US) | 1986-11-25 | — | — | US | disclosed |
| EP-0145978-A2 | Nucleoside process | Bristol-Myers Company (US) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | PNP 15/4885MPO 1577/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | PNP 15/4885MPO 1577/4885 |
| US-20260146249-A1 | ANTISENSE OLIGONUCLEOTIDES FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH AN ABNORMAL PROCESSING OF APP | APP, PSEN2, PSEN1 | PNP 243/4885MPO 4076/4885 |
| US-20260048076-A1 | METHODS FOR DECREASING OR INHIBITING HUMAN L1 RETROTRANSPOSON RNA AND COMPOSITIONS FOR USE THEREIN | POT1, FBL, HNRNPA1 | PNP 182/4885MPO 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.